Altered regulation of PDK4 expression promotes antiestrogen resistance in human breast cancer cells

[1]  L. Cesaro,et al.  Quantitative analysis of a phosphoproteome readily altered by the protein kinase CK2 inhibitor quinalizarin in HEK-293T cells. , 2015, Biochimica et biophysica acta.

[2]  D. Koh,et al.  ZBTB2 increases PDK4 expression by transcriptional repression of RelA/p65 , 2015, Nucleic acids research.

[3]  M. Specht,et al.  Case records of the Massachusetts General Hospital. Case 1-2015. A 66-year-old woman with metastatic breast cancer after endocrine therapy. , 2015, The New England journal of medicine.

[4]  J. Settleman,et al.  Metabolic and transcriptional profiling reveals pyruvate dehydrogenase kinase 4 as a mediator of epithelial-mesenchymal transition and drug resistance in tumor cells , 2014, Cancer & metabolism.

[5]  Mingming Jia,et al.  COSMIC: exploring the world's knowledge of somatic mutations in human cancer , 2014, Nucleic Acids Res..

[6]  R. Clarke,et al.  MYC regulates the unfolded protein response and glucose and glutamine uptake in endocrine resistant breast cancer , 2014, Molecular Cancer.

[7]  R. Deberardinis,et al.  Inhibition of cancer cell proliferation by PPARγ is mediated by a metabolic switch that increases reactive oxygen species levels. , 2014, Cell metabolism.

[8]  Takashi Suzuki,et al.  Increased androgen receptor activity and cell proliferation in aromatase inhibitor-resistant breast carcinoma , 2014, The Journal of Steroid Biochemistry and Molecular Biology.

[9]  Hongbing Zhang,et al.  PDK4 Protein Promotes Tumorigenesis through Activation of cAMP-response Element-binding Protein (CREB)-Ras Homolog Enriched in Brain (RHEB)-mTORC1 Signaling Cascade*♦ , 2014, The Journal of Biological Chemistry.

[10]  P. Puigserver,et al.  Cyclin D1-CDK4 Controls Glucose Metabolism Independently of Cell Cycle Progression , 2014, Nature.

[11]  E. Pasquale,et al.  Association of the Breast Cancer Antiestrogen Resistance Protein 1 (BCAR1) and BCAR3 Scaffolding Proteins in Cell Signaling and Antiestrogen Resistance* , 2014, The Journal of Biological Chemistry.

[12]  W. Zwart,et al.  Tamoxifen resistance: from bench to bedside. , 2013, European journal of pharmacology.

[13]  Amy R. Peck,et al.  Prolactin-Stat5 signaling in breast cancer is potently disrupted by acidosis within the tumor microenvironment , 2013, Breast Cancer Research.

[14]  L. Fan,et al.  Extended adjuvant endocrine therapy in hormone-receptor positive breast cancer. , 2013, Breast.

[15]  Ja Hee Lee,et al.  Hypoxia Induces PDK4 Gene Expression through Induction of the Orphan Nuclear Receptor ERRγ , 2012, PloS one.

[16]  D. Yee,et al.  Acquired resistance to tamoxifen is associated with loss of the type I insulin-like growth factor receptor: implications for breast cancer treatment. , 2012, Cancer research.

[17]  A. Sivachenko,et al.  Sequence analysis of mutations and translocations across breast cancer subtypes , 2012, Nature.

[18]  S. Fuqua,et al.  Phosphorylated and sumoylation-deficient progesterone receptors drive proliferative gene signatures during breast cancer progression , 2012, Breast Cancer Research.

[19]  M. Higuchi,et al.  The awakening of an advanced malignant cancer: an insult to the mitochondrial genome. , 2012, Biochimica et biophysica acta.

[20]  K. Sahlin,et al.  The effect of continuous and interval exercise on PGC‐1α and PDK4 mRNA in type I and type II fibres of human skeletal muscle , 2012, Acta physiologica.

[21]  Bin Zhang,et al.  PhosphoSitePlus: a comprehensive resource for investigating the structure and function of experimentally determined post-translational modifications in man and mouse , 2011, Nucleic Acids Res..

[22]  F. Sotgia,et al.  Anti-estrogen resistance in breast cancer is induced by the tumor microenvironment and can be overcome by inhibiting mitochondrial function in epithelial cancer cells , 2011, Cancer biology & therapy.

[23]  Hao Liu,et al.  Mitochondrial DNA Content Varies with Pathological Characteristics of Breast Cancer , 2011, Journal of oncology.

[24]  Andrew Skildum,et al.  Mitochondrial amplification selectively increases doxorubicin sensitivity in breast cancer cells with acquired antiestrogen resistance , 2011, Breast Cancer Research and Treatment.

[25]  M. Fernö,et al.  A non-functional retinoblastoma tumor suppressor (RB) pathway in premenopausal breast cancer is associated with resistance to tamoxifen , 2011, Cell cycle.

[26]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[27]  Yu Shyr,et al.  A Gene Expression Signature from Human Breast Cancer Cells with Acquired Hormone Independence Identifies MYC as a Mediator of Antiestrogen Resistance , 2011, Clinical Cancer Research.

[28]  A. Giordano,et al.  Molecular Mechanism and Clinical Implications of Endocrine Therapy Resistance in Breast Cancer , 2010, Oncology.

[29]  Jun Li,et al.  Pyruvate Dehydrogenase Kinase-4 Structures Reveal a Metastable Open Conformation Fostering Robust Core-free Basal Activity* , 2008, Journal of Biological Chemistry.

[30]  S A Forbes,et al.  The Catalogue of Somatic Mutations in Cancer (COSMIC) , 2008, Current protocols in human genetics.

[31]  P. Argani,et al.  Tamoxifen-stimulated growth of breast cancer due to p21 loss , 2008, Proceedings of the National Academy of Sciences.

[32]  B. O’Malley,et al.  Selective estrogen-receptor modulators and antihormonal resistance in breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  H. Varma,et al.  Functional Ablation of pRb Activates Cdk2 and Causes Antiestrogen Resistance in Human Breast Cancer Cells , 2007, PloS one.

[34]  D. El-Ashry,et al.  Reversal of the Estrogen Receptor–Negative Phenotype in Breast Cancer and Restoration of Antiestrogen Response , 2007, Clinical Cancer Research.

[35]  Gordon B. Mills,et al.  Src promotes estrogen-dependent estrogen receptor α proteolysis in human breast cancer , 2007 .

[36]  Yvonne Will,et al.  Circumventing the Crabtree effect: replacing media glucose with galactose increases susceptibility of HepG2 cells to mitochondrial toxicants. , 2007, Toxicological sciences : an official journal of the Society of Toxicology.

[37]  Ke Ma,et al.  Estrogen-related Receptors Stimulate Pyruvate Dehydrogenase Kinase Isoform 4 Gene Expression* , 2006, Journal of Biological Chemistry.

[38]  Chenguang Wang,et al.  Cyclin D1 repression of nuclear respiratory factor 1 integrates nuclear DNA synthesis and mitochondrial function. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[39]  T. Roche,et al.  Ligand-induced Effects on Pyruvate Dehydrogenase Kinase Isoform 2* , 2006, Journal of Biological Chemistry.

[40]  G. Semenza,et al.  HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. , 2006, Cell metabolism.

[41]  A. Sahin,et al.  Tissue transglutaminase-induced alterations in extracellular matrix inhibit tumor invasion , 2005, Molecular Cancer.

[42]  D. Chuang,et al.  Crystal structure of pyruvate dehydrogenase kinase 3 bound to lipoyl domain 2 of human pyruvate dehydrogenase complex , 2005, The EMBO journal.

[43]  Y Wang,et al.  Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.

[44]  S. Conrad,et al.  c-Myc Suppresses p21WAF1/CIP1 Expression during Estrogen Signaling and Antiestrogen Resistance in Human Breast Cancer Cells* , 2005, Journal of Biological Chemistry.

[45]  C. Lange,et al.  Progesterone receptors induce cell cycle progression via activation of mitogen-activated protein kinases. , 2005, Molecular endocrinology.

[46]  R. Clarke,et al.  The nuclear factor κB inhibitor parthenolide restores ICI 182,780 (Faslodex; fulvestrant)–induced apoptosis in antiestrogen-resistant breast cancer cells , 2005, Molecular Cancer Therapeutics.

[47]  R. Clarke,et al.  Expression of an estrogen receptor variant lacking exon 3 in derivatives of MCF-7 cells with acquired estrogen independence or tamoxifen resistance. , 2004, Journal of molecular endocrinology.

[48]  P. Neufer,et al.  Transcriptional regulation of pyruvate dehydrogenase kinase 4 in skeletal muscle during and after exercise , 2004, The Proceedings of the Nutrition Society.

[49]  Robert A. Harris,et al.  Protein kinase B-alpha inhibits human pyruvate dehydrogenase kinase-4 gene induction by dexamethasone through inactivation of FOXO transcription factors. , 2004, Diabetes.

[50]  A. Lykkesfeldt,et al.  Resistance to different antiestrogens is caused by different multi-factorial changes and is associated with reduced expression of IGF receptor Ialpha. , 2003, Endocrine-related cancer.

[51]  D. Alessi,et al.  Deficiency of PDK1 in cardiac muscle results in heart failure and increased sensitivity to hypoxia , 2003, The EMBO journal.

[52]  M. Buck,et al.  Coordinate expression of the PDK4 gene: a means of regulating fuel selection in a hibernating mammal. , 2002, Physiological genomics.

[53]  G. Kroemer,et al.  Apoptosis-inducing factor (AIF): a novel caspase-independent death effector released from mitochondria. , 2002, Biochimie.

[54]  V. Giguère,et al.  4-Hydroxytamoxifen Is an Isoform-Specific Inhibitor of Orphan Estrogen-Receptor-Related (ERR) Nuclear Receptors β and γ. , 2001, Endocrinology.

[55]  F. Kern,et al.  Hyperactivation of MAPK Induces Loss of ERα Expression in Breast Cancer Cells , 2001 .

[56]  J. Lehmann,et al.  4-Hydroxytamoxifen binds to and deactivates the estrogen-related receptor γ , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[57]  S. van der Flier,et al.  BCAR1, a human homologue of the adapter protein p130Cas, and antiestrogen resistance in breast cancer cells. , 2000, Journal of the National Cancer Institute.

[58]  K. M. Popov,et al.  Insulin downregulates pyruvate dehydrogenase kinase (PDK) mRNA: potential mechanism contributing to increased lipid oxidation in insulin-resistant subjects. , 1998, Molecular genetics and metabolism.

[59]  J Lippman,et al.  MCF7/LCC9: an antiestrogen-resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182,780 confers an early cross-resistance to the nonsteroidal antiestrogen tamoxifen. , 1997, Cancer research.

[60]  R. Sutherland,et al.  Inducible overexpression of cyclin D1 in breast cancer cells reverses the growth-inhibitory effects of antiestrogens. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[61]  K. M. Popov,et al.  Cloning and Characterization of PDK4 on 7q21.3 Encoding a Fourth Pyruvate Dehydrogenase Kinase Isoenzyme in Human* , 1996, The Journal of Biological Chemistry.

[62]  P. Frey.  The Leloir pathway: a mechanistic imperative for three enzymes to change the stereochemical configuration of a single carbon in galactose , 1996, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[63]  R. Santen,et al.  Letrozole (CGS 20267). A phase I study of a new potent oral aromatase inhibitor of breast cancer , 1995, Cancer.

[64]  C. Osborne,et al.  Mechanisms for tamoxifen resistance in breast cancer: Possible role of tamoxifen metabolism , 1993, The Journal of Steroid Biochemistry and Molecular Biology.

[65]  D. Edwards,et al.  The steroid antagonist RU486 exerts different effects on the glucocorticoid and progesterone receptors. , 1993, Endocrinology.

[66]  W. McGuire,et al.  Tamoxifen and the isomers of 4-hydroxytamoxifen in tamoxifen-resistant tumors from breast cancer patients. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[67]  C. Benz,et al.  Truncated forms of DNA-binding estrogen receptors in human breast cancer. , 1991, The Journal of clinical investigation.

[68]  A. Wakeling,et al.  A potent specific pure antiestrogen with clinical potential. , 1991, Cancer research.

[69]  R. Santen,et al.  Medical Adrenalectomy with Aminoglutethimide: Clinical Studies in Postmenopausal Patients with Metastatic Breast Carcinoma , 1978, Annals of surgery.

[70]  V. Jordan,et al.  Tamoxifen (ICI 46,474) and the human carcinoma 8S oestrogen receptor. , 1975, European journal of cancer.

[71]  A. Long,et al.  A human cell line from a pleural effusion derived from a breast carcinoma. , 1973, Journal of the National Cancer Institute.

[72]  R. Deberardinis,et al.  The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. , 2008, Cell metabolism.

[73]  Gordon B Mills,et al.  Src promotes estrogen-dependent estrogen receptor alpha proteolysis in human breast cancer. , 2007, The Journal of clinical investigation.

[74]  Robert Clarke,et al.  The nuclear factor kappa B inhibitor parthenolide restores ICI 182,780 (Faslodex; fulvestrant)-induced apoptosis in antiestrogen-resistant breast cancer cells. , 2005, Molecular cancer therapeutics.

[75]  V. Giguère,et al.  4-Hydroxytamoxifen is an isoform-specific inhibitor of orphan estrogen-receptor-related (ERR) nuclear receptors beta and gamma. , 2001, Endocrinology.

[76]  A. Oh,et al.  Hyperactivation of MAPK induces loss of ERalpha expression in breast cancer cells. , 2001, Molecular endocrinology.

[77]  K. M. Popov,et al.  Starvation and diabetes increase the amount of pyruvate dehydrogenase kinase isoenzyme 4 in rat heart. , 1998, The Biochemical journal.